Will Recent Board Changes at Bausch + Lomb (BLCO) Shift Its Governance Approach or Strategic Priorities?

• Bausch + Lomb announced that Brett M. Icahn and Gary Hu, both affiliated with Carl Icahn, have resigned from its Board of Directors after the Icahn group’s equity stake in parent company Bausch Health Companies Inc. fell below a required level.
• This departure reduces the influence of a prominent activist investor group and signals a possible shift in the company’s governance and oversight.
• We'll explore how the exit of Icahn-linked directors may impact Bausch + Lomb’s investment narrative and future board direction.

Find companies with promising cash flow potential yet trading below their fair value.

What Is Bausch + Lomb's Investment Narrative?

Bausch + Lomb’s investment story has centered on gradual improvement in financial results and a busy product pipeline in eye care. For many investors, the core belief is that steady revenue growth, ongoing launches like LUMIFY Preservative Free, and operational refinancings offer meaningful upside as the company aims for profitability in the coming years. The recent resignation of the Icahn-affiliated directors following a reduced stake is unlikely to materially shift short-term catalysts, such as new product rollouts or the path to profitability, with board independence and experience remaining strong. However, the exit does reduce the influence of activist oversight, which may change how risks like profitability timelines and capital allocation are perceived. Unless governance priorities change in response, the key metrics and risks for investors remain grounded in revenue growth, margin improvement, and new product success.

But behind the improved results, profitability remains a critical hurdle that investors should watch closely. Bausch + Lomb's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two members of the Simply Wall St Community offered fair value targets ranging from US$15.14 up to a very large US$37.68 per share. This wide spread illustrates how expectations about profitability and execution can widely influence company outlooks, especially with recent shifts in board oversight. Consider the range of opinions and how future governance could reshape the investment case.

Explore 2 other fair value estimates on Bausch + Lomb - why the stock might be worth just $15.14!

Build Your Own Bausch + Lomb Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 26 companies in the world exploring or producing it. Find the list for free.
• We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com